Drug R&D Models Will Change Drastically By 2020, PwC Report Predicts
The pharmaceutical industry is about to face a world in which successful companies no longer focus on blockbusters, drugs are approved in stages for an ever widening patient population, and large sales teams have been replaced by advisers, according to a report by PricewaterhouseCooper
You may also be interested in...
Lilly's independently operating Chorus drug development unit has created a means to mitigate the risk of drug development by conducting small-scale, targeted experiments separate from the larger R&D organization
Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act
Our infographic illustrates the recommendations in FDA’s COVID-19 pandemic recovery and preparedness plan, ranging from strengthening the EUA process to managing the backlog of pending inspections.